Feasibility of Automated Image-Based Red Bone Marrow Dosimetry for [177Lu]Lu-PSMA Radiopharmaceutical Therapy of Metastatic Castration-Resistant Prostate Cancer
Cancers · 11.07.2025 · 17 (14) · 2313
DOI: 10.3390/cancers17142313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 11.07.2025. Verfasst von Mikhail Rumiantcev und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Projekt DEAL.
Abstract (Originalsprache)
Background/Objectives: Red bone marrow irradiation is a major concern for patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA therapy. However, low uptake in the red bone marrow and the presence of bone lesions complicate image-based red bone marrow dosimetry. This study aimed to investigate the general feasibility of image-based red bone marrow activity estimation for [177Lu]Lu-PSMA treatment and to develop a fully automated workflow for clinical implementation.
Methods
In the first part of the study, 175 virtual patient phantoms with realistic 177Lu activity distributions were generated based on 639 pre-therapeutic [18F]F-PSMA-1007 PET/CT scans. The SIMIND Monte Carlo tool was used to simulate the 177Lu SPECT acquisitions (24 h post-injection (p.i.)), which were used to assess the uncertainty of red bone marrow activity estimation. In the second part, red bone marrow self- and cross-absorbed doses were estimated for four therapy cycles of 20 patients.
Results
The simulation study shows a significant overestimation of activity in skeletal sites with bone lesions, with median recovery coefficients (RCs) across all phantoms yielding a median of 225% (range: 106–1015%). In contrast, the median RCs were markedly lower in skeletal sites neighboring or distant to lesion-carrying sites (105% [72–163%] and 107% [77–130%], respectively). The median total absorbed dose to the red bone marrow was 20.8 mGy/GBq (range: 5.6–297.9 mGy/GBq). Median blood levels decreased with an increasing median cumulative total absorbed dose.
Conclusions
Reliable estimation of activity concentration in skeletal sites without bone lesion infiltration has been shown to be feasible. Based on this finding, an automated workflow for routine image-based red bone marrow dosimetry was developed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.
- The Russell H. Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine and Molecular Imaging, John Hopkins School of Medicine, Baltimore, MD 21287, USA.
- Clinic for Nuclear Medicine, Hannover Medical School (MHH), 30625 Hannover, Germany.
ORCID-Profile: Mikhail Rumiantcev, Guido Böning
Förderung
- German Research Foundation
- Projekt DEAL
Zitieren
APA
Rumiantcev, M., Resch, S., Liubchenko, G., Sheikh, G., Zacherl, M., Werner, R. A., Ziegler, S. I., Böning, G., & Delker, A. (2025). Feasibility of Automated Image-Based Red Bone Marrow Dosimetry for [177Lu]Lu-PSMA Radiopharmaceutical Therapy of Metastatic Castration-Resistant Prostate Cancer. Cancers, 17(14), 2313. https://doi.org/10.3390/cancers17142313
Vancouver
Rumiantcev M, Resch S, Liubchenko G, Sheikh G, Zacherl M, Werner RA, et al. Feasibility of Automated Image-Based Red Bone Marrow Dosimetry for [177Lu]Lu-PSMA Radiopharmaceutical Therapy of Metastatic Castration-Resistant Prostate Cancer. Cancers. 2025;17(14):2313. doi:10.3390/cancers17142313
BibTeX
@article{Rumiantcev2025,
author = {Rumiantcev, Mikhail and Resch, Sandra and Liubchenko, Grigory and Sheikh, Gabriel and Zacherl, Mathias and Werner, Rudolf A and Ziegler, Sibylle I and Böning, Guido and Delker, Astrid},
title = {Feasibility of Automated Image-Based Red Bone Marrow Dosimetry for [177Lu]Lu-PSMA Radiopharmaceutical Therapy of Metastatic Castration-Resistant Prostate Cancer},
journal = {Cancers},
year = {2025},
volume = {17},
number = {14},
pages = {2313},
doi = {10.3390/cancers17142313}
}
EUVIMED